Abstract
dyspepsia. Several therapeutic regimens have been offered for eradication of H. Pylori. There are
several reports of resistance of H. Pylori to metronidazole in Iran, so other therapeutic regimens
have been offered. We compared Furazolidone versus Tetracycline, in quadruple regimen
[Omeprazole-Amoxicillin-Bismuth subcitrate-Tetracycline (OAB-T) vs. [Omeprazole-Amoxicillin-
Bismuth subcitrate-Furazolidone (OAB-F)].
Materials and Methods: In a clinical trial study we treated 109 H. Pylori infected patients with
dyspepsia in Zahedan Khatam-ol-Anbia Hospital in two therapeutic groups. The first group
received Omeprazole 20 mg BID, Bismuth subcitrate 200 mg Q6h, Amoxicillin 1 gr Q12h,
Furazolidone 100 mg Q12h. The second group received Omeprazole 20 mg BID, Bismuth
subcitrate 200 mg Q6h, Amoxicillin 1 gr Q12h, Tetracycline 500 mg Q 12h.
Results: There were 49 patients in OAB-F group and 51 patients in OAB-T group. H. Pylori
eradication rate based on H. Pylori fecal Ag Test negativity was 85.7% and 80.4% in OAB-F &
OAB-T groups respectively.
Discussion: Furazolidone-based regimen is effective in H. Pylori eradication. With respect to
low price and availability of Furazolidone, Furazolidone- based Quadruple therapy is an
acceptable regimen in communities with high metronidazole resistance.
Keywords
H. Pylori Eradication regimen Dyspepsia Furazolidone Tetracycline
Fulltext
The full text of this article is available on the PDF file.
References
-
1.
The References of this article are available on the PDF file.